Patients monitoring during treatment with Teriflunomide (ORP-41)
These treatments may be used as sequential monotherapies or for escalation or induction strategies based on the efficacy and safety measures showed significant reductions in disability progression, relapse rates,and magnetic resonance imaging measures of disease activity. In keeping with this primar...
Main Author: | Nahid Hoseini Nejad Mir |
---|---|
Format: | Article |
Language: | English |
Published: |
Iran University of Medical Sciences
2023-01-01
|
Series: | Neurology Letters |
Subjects: | |
Online Access: | https://www.neurologyletters.com/article_184682_d41d8cd98f00b204e9800998ecf8427e.pdf |
Similar Items
-
Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis
by: Giancarlo Comi, et al.
Published: (2020-10-01) -
TERIFLUNOMIDE - A NEW TABLETED DRUG FOR THERAPY OF REMITTING DISSEMINATED SCLEROSIS (REVIEW)
by: E. V. POPOVA, et al.
Published: (2016-12-01) -
Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide
by: Carlo Tornatore, et al.
Published: (2022-02-01) -
Meccanismo d’azione dei farmaci più recenti, Teriflunomide e Alemtuzumab e implicazioni terapeutiche
by: Francesco Patti
Published: (2015-11-01) -
Teriflunomide as a therapeutic means for myelin repair
by: Peter Göttle, et al.
Published: (2023-01-01)